XKRX
007390
Market cap1.18bUSD
Oct 08, Last price
24,550.00KRW
1D
-0.61%
1Q
-2.58%
Jan 2017
427.39%
Name
NatureCell Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Seoul, South Korea, NatureCell Co.,Ltd. operates globally, manufacturing and distributing a diverse range of products alongside specialized services. The company's consumer goods portfolio includes canned and health-enhancing functional foods, various beverages such as fruit, aloe vera, coffee, and energy drinks, as well as Korean sauces. They also produce cosmetics and are involved in the stem cell product market. These offerings are marketed under both the SAMMI brand and through OEM agreements. Furthermore, NatureCell provides expert services for the cryopreservation of blood cells, specifically endothelial progenitor cells, mononuclear cells, and platelet-rich plasma products. Established in 1960, the company was formerly known as RNL Sammi CO., Ltd. before adopting its current name, NatureCell Co.,Ltd., in April 2013.
Key people
Sang Mok Jung
President, Director · since 2025
Dae Jung Byun
Chief Executive Officer, Director · since 2024
Yong Geun Choi
Internal Auditor · since 2013
Byeong Ha Jang
Internal Auditor · since 2023
Nam Su Kim
Assistant Managing Director · since 2010
Seung Min Kim
Director · since 2023
Sang Cheol Park
Director · since 2023
Jeong Chan Rah
Director · since 2025
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||